IRIS Accounts Production v25.1.3.33 SC472060 Board of Directors 1.1.24 31.12.24 31.12.24 4.6.25 false true false false true false Auditors Opinion Ordinary 0.0100 0.0100 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC4720602023-12-31SC4720602024-12-31SC4720602024-01-012024-12-31SC4720602022-12-31SC4720602023-01-012023-12-31SC4720602023-12-31SC472060ns15:Scotland2024-01-012024-12-31SC472060ns14:PoundSterling2024-01-012024-12-31SC472060ns10:Director12024-01-012024-12-31SC472060ns10:PrivateLimitedCompanyLtd2024-01-012024-12-31SC472060ns10:SmallEntities2024-01-012024-12-31SC472060ns10:Audited2024-01-012024-12-31SC472060ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-31SC472060ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-31SC472060ns10:AbridgedAccounts2024-01-012024-12-31SC472060ns10:OrdinaryShareClass12024-01-012024-12-31SC47206011ns10:OrdinaryShareClass12024-01-012024-12-31SC472060ns10:Director22024-01-012024-12-31SC472060ns10:Director32024-01-012024-12-31SC472060ns10:Director42024-01-012024-12-31SC472060ns10:Director52024-01-012024-12-31SC472060ns10:Director72024-01-012024-12-31SC472060ns10:Director82024-01-012024-12-31SC472060ns10:Director92024-01-012024-12-31SC472060ns10:Director102024-01-012024-12-31SC472060ns10:CompanySecretary12024-01-012024-12-31SC472060ns10:RegisteredOffice2024-01-012024-12-31SC472060ns5:CurrentFinancialInstruments2024-12-31SC472060ns5:CurrentFinancialInstruments2023-12-31SC472060ns5:ShareCapital2024-12-31SC472060ns5:ShareCapital2023-12-31SC472060ns5:SharePremium2024-12-31SC472060ns5:SharePremium2023-12-31SC472060ns5:FurtherSpecificReserve3ComponentTotalEquity2024-12-31SC472060ns5:FurtherSpecificReserve3ComponentTotalEquity2023-12-31SC472060ns5:RetainedEarningsAccumulatedLosses2024-12-31SC472060ns5:RetainedEarningsAccumulatedLosses2023-12-31SC47206012024-01-012024-12-31SC472060ns5:WithinOneYear2024-12-31SC472060ns5:WithinOneYear2023-12-31SC472060ns5:BetweenOneFiveYears2024-12-31SC472060ns5:BetweenOneFiveYears2023-12-31SC472060ns5:MoreThanFiveYears2024-12-31SC472060ns5:MoreThanFiveYears2023-12-31SC472060ns5:AllPeriods2024-12-31SC472060ns5:AllPeriods2023-12-31SC472060ns10:OrdinaryShareClass12024-12-31SC472060ns5:FurtherSpecificReserve3ComponentTotalEquity2023-12-31
REGISTERED NUMBER: SC472060 (Scotland)















Financial Statements for the Year Ended 31 December 2024

for

Synaptec Ltd

Synaptec Ltd (Registered number: SC472060)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Abridged Statement of Financial Position 2

Notes to the Financial Statements 3


Synaptec Ltd

Company Information
for the Year Ended 31 December 2024







DIRECTORS: P J G Orr
Dr C Booth
N A Ellis
Dr P Niewczas
D C N Pratt
D M Larssen
J McPhillimy
R W Finesy
J J C Simpson





SECRETARY: P J G Orr





REGISTERED OFFICE: 2 Atlantic Square
31 York Street
Glasgow
G2 8AS





REGISTERED NUMBER: SC472060 (Scotland)





AUDITORS: Johnston Carmichael LLP
227 West George Street
Glasgow
G2 2ND

Synaptec Ltd (Registered number: SC472060)

Abridged Statement of Financial Position
31 December 2024

31.12.24 31.12.23
Notes £    £    £   
FIXED ASSETS
Tangible assets 4 459,950 160,014
Investments 5 250 250
460,200 160,264

CURRENT ASSETS
Stocks 600,535 419,577
Debtors 1,813,722 981,483
Investments 2,000,000 -
Cash at bank 1,010,473 799,214
5,424,730 2,200,274
CREDITORS
Amounts falling due within one year 1,242,824 536,591
NET CURRENT ASSETS 4,181,906 1,663,683
TOTAL ASSETS LESS CURRENT
LIABILITIES

4,642,106

1,823,947

CAPITAL AND RESERVES
Called up share capital 7 354 284
Share premium 9,927,790 5,640,058
Share based payments reserve 8 384,026 303,001
Retained earnings (5,670,064 ) (4,119,396 )
SHAREHOLDERS' FUNDS 4,642,106 1,823,947

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Statement of Comprehensive Income and an abridged Statement of Financial Position for the year ended 31 December 2024 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 June 2025 and were signed on its behalf by:





P J G Orr - Director


Synaptec Ltd (Registered number: SC472060)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Synaptec Ltd is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors’ are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Valuation of stock
The valuation of stock requires the directors to exercise judgement in capitalising various categories of expenditure. Costs capitalised include raw materials, direct and indirect labour, and an apportionment of overheads. Estimations around stock are reviewed frequently to ensure that they remain appropriate and that the cost of stock is not in excess of its net realisable value.

Valuation of share options
Fair values used in calculating the amount to be expensed as a share-based payment is subject to a level of uncertainty. The company is required to calculate the fair value of the equity-settled instruments granted to employees in terms of the share option schemes. These fair values are calculated by applying a valuation model, which is in itself judgmental, and takes into account certain inherently uncertain assumptions. Estimations around share-based payments are reviewed yearly to ensure that these remain appropriate within the financial statements.

Turnover
Turnover represents income from the sale of the company's products and is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business. Turnover is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Where product sales include predetermined milestones such as product testing or installation, turnover is recognised on completion of these milestones.

Synaptec Ltd (Registered number: SC472060)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Tangible fixed assets are stated at historical cost less accumulated depreciation and any impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged to profit or loss over the estimated useful life economic lives as follows-

- Plant and machinery - Over 3 to 5 years on straight line basis
- Computer and equipment - Over 2 to 3 years on straight line basis
- Long term leasehold - Over 5 years on straight line basis.

Basic financial liability
Basic financial liabilities, including certain creditors and other loans, are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortized. Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Government grants
Government grants are recognsied at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

Government grants relating to turnover are recognised as income over the periods when the related costs are incurred.

Investments in subsidiaries
Investments in subsidiaries are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals or impairment losses are recognised immediately in the profit and loss account.

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost includes expenditure incurred in acquiring the stocks, production or conversion costs and other costs in bringing them to their existing location and condition .

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its estimated selling price less costs to complete and sell. The impairment is recognized immediately within profit and loss.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Research and Development tax credits are recognised at the fair value of the asset received or receivable when there is reasonable assurance that claims will be successful.


Synaptec Ltd (Registered number: SC472060)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Transactions in foreign currencies are translated to the company's functional currency at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Foreign exchange differences arising on translation are recognized in profit or loss.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Investments
Cash held on long-term deposits represents amounts placed with financial institutions with original maturity terms exceeding three months. These deposits are classified as financial assets and measured at amortised cost.

Going concern
The directors believe the company has adequate resources to continue in operational existence for the foreseeable future, being a period of at least 12 months from the signing of the financial statements.

In forming this assessment, the directors have considered existing company resources as well as trading and cash flow projections. The Directors have achieved a strong pipeline of work over the going concern period. Whilst the directors are aware that further funding may be required to support the company through its scale up phase they remain confident in the company’s ability to manage costs effectively. A significant proportion of the company’s costs are either within direct control or fixed for the period of Management’s assessment, which, combined with other levers available to the Directors to adjust expenditure, gives the Directors sufficient confidence in the company’s available headroom over the forecast period.

Based on the above factors, the directors deem it appropriate to continue to prepare the financial statements on a going concern basis.

Share-based payments
Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted. Where material, the fair value determined at the grant date is expensed on a straight-line basis over the vesting period, 3 years, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 38 (2023 - 32 ) .

Synaptec Ltd (Registered number: SC472060)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 January 2024 350,410
Additions 387,991
Disposals (166 )
At 31 December 2024 738,235
DEPRECIATION
At 1 January 2024 190,396
Charge for year 88,012
Eliminated on disposal (123 )
At 31 December 2024 278,285
NET BOOK VALUE
At 31 December 2024 459,950
At 31 December 2023 160,014

5. FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:
Totals
£   
COST
At 1 January 2024
and 31 December 2024 250
NET BOOK VALUE
At 31 December 2024 250
At 31 December 2023 250

Synaptec Ltd is the ultimate group holding company of the Synaptec Group. Synaptec Ltd has one wholly owned subsidiary, Synaptec Instruments Ltd SC684349, registered in Scotland. Synaptec Instruments Ltd is currently dormant.

6. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
31.12.24 31.12.23
£    £   
Within one year 93,313 -
Between one and five years 593,605 -
In more than five years 457,870 -
1,144,788 -

Synaptec Ltd (Registered number: SC472060)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.12.24 31.12.23
value: £    £   
354,292 Ordinary £0.00 1 354 284

70,147 Ordinary shares of £0.001 each were allotted as fully paid at a premium of £61.84 per share during the year.

The company operates an equity settled EMI Share Option Scheme. During the year, 10,500 (2023 - 3,674) share options were granted to employees by the company. At 31 December 2024, the total number of options outstanding under the scheme was 23,557 (2023 - 13,157) with an exercise price ranging between £12.48 and £61.85. The share options vest on their grant date but can only be exercised on certain exit events or at the discretion of the board.

8. RESERVES
Share
based
payments
reserve
£   
At 1 January 2024 303,001
Credit to equity for equity settled share
based payment transactions

81,025


At 31 December 2024 384,026

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

James Hamilton (Senior Statutory Auditor)
for and on behalf of Johnston Carmichael LLP